On January 17, 2024, Eterna Therapeutics Inc. received a notice (the Notice) from the Listing Qualifications Staff (Staff) of The Nasdaq Stock Market LLC (Nasdaq) stating that, due to the appointment of Dorothy Clarke as the company?s general counsel, Ms. Clarke?s subsequent resignation from the committees of the company?s board of directors (the board) and the appointment of Sanjeev Luther as a member of the board, the company no longer complies with Nasdaq?s majority independent board and independent audit committee requirements as set forth in Nasdaq Listing Rule 5605.